Global Blood Therapeutics (GBT) Misses Q4 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Global Blood Therapeutics (GBT) PT Lowered to $67 at Cowen
February 24, 2022 6:55 AM ESTCowen analyst Ritu Baral lowered the price target on Global Blood Therapeutics (NASDAQ: GBT) to $67.00 (from $72.00) while maintaining an Outperform rating.
The analyst commented, "GBT reported Q4 Oxbryta sales of $56.1MM (+8% q/q), in line with guidance. NRxs were down... More
